Home / Publications / Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance

Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance

Olga Alexandrovna Kraevaya 1
Olga Alexandrovna Kraevaya
, 
Ekaterina Aleksandrovna Khakina 2
Ekaterina Aleksandrovna Khakina
, 
Nikita Alexandrovich Emelianov 1
Nikita Alexandrovich Emelianov
, 
Alexander Fedorovich Shestakov 1, 3
Alexander Fedorovich Shestakov
, 
Tatiana Evgen'evna Sashenkova 1
Tatiana Evgen'evna Sashenkova
, 
Denis Valeryevich Mishchenko 1, 3, 4
Denis Valeryevich Mishchenko
, 
Pavel Anatol'evich Troshin 1, 5
Pavel Anatol'evich Troshin
1 Federal Research Center of Problems of Chemical Physics and Medicinal Chemistry, Russian Academy of Sciences, Chernogolovka, Moscow Region, Russian Federation
2 A.N. Nesmeyanov Institute of Organoelement Compounds of Russian Academy of Sciences, Moscow, Russian Federation
3 Department of Fundamental Physical and Chemical Engineering, M.V. Lomonosov Moscow State University, Moscow, Russian Federation
4 Moscow Region State Pedagogical University, Mytishi, Moscow Region, Russian Federation
5 Zhengzhou Research Institute, Harbin Institute of Technology, Zhengzhou, China
10.1016/j.mencom.2024.02.006
Published 2024-02-19
Communication , Volume 34, Issue 2, 178-180
2
Share
Cite this
GOST
 | 
Cite this
GOST Copy
Kraevaya O. A. et al. Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance // Mendeleev Communications. 2024. Vol. 34. No. 2. pp. 178-180.
GOST all authors (up to 50) Copy
Kraevaya O. A., Khakina E. A., Emelianov N. A., Shestakov A. F., Sashenkova T. E., Mishchenko D. V., Troshin P. A. Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance // Mendeleev Communications. 2024. Vol. 34. No. 2. pp. 178-180.
RIS
 | 
Cite this
RIS Copy
TY - JOUR
DO - 10.1016/j.mencom.2024.02.006
UR - https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.02.006
TI - Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance
T2 - Mendeleev Communications
AU - Kraevaya, Olga Alexandrovna
AU - Khakina, Ekaterina Aleksandrovna
AU - Emelianov, Nikita Alexandrovich
AU - Shestakov, Alexander Fedorovich
AU - Sashenkova, Tatiana Evgen'evna
AU - Mishchenko, Denis Valeryevich
AU - Troshin, Pavel Anatol'evich
PY - 2024
DA - 2024/02/19
PB - Mendeleev Communications
SP - 178-180
IS - 2
VL - 34
ER -
BibTex
 | 
Cite this
BibTex (up to 50 authors) Copy
@article{2024_Kraevaya,
author = {Olga Alexandrovna Kraevaya and Ekaterina Aleksandrovna Khakina and Nikita Alexandrovich Emelianov and Alexander Fedorovich Shestakov and Tatiana Evgen'evna Sashenkova and Denis Valeryevich Mishchenko and Pavel Anatol'evich Troshin},
title = {Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance},
journal = {Mendeleev Communications},
year = {2024},
volume = {34},
publisher = {Mendeleev Communications},
month = {Feb},
url = {https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.02.006},
number = {2},
pages = {178--180},
doi = {10.1016/j.mencom.2024.02.006}
}
MLA
Cite this
MLA Copy
Kraevaya, Olga Alexandrovna, et al. “Integration of anticancer drug ruboxyl into the membrane of fullerene-based vesicle enhances its therapeutic performance.” Mendeleev Communications, vol. 34, no. 2, Feb. 2024, pp. 178-180. https://mendcomm.colab.ws/publications/10.1016/j.mencom.2024.02.006.

Keywords

IR s-SNOM.
leukemia
ruboxyl
vesicles
water-soluble fullerene derivative

Abstract

The supramolecular complexation of anthracycline antibiotic ruboxyl with water-soluble fullerene derivative was visualized by scattering scanning near-field optical microscopy, and the effects of this complexation on the antileukemic activity in vivo were evaluated. Treatment of mice with P388 lymphocytic leukemia with ruboxyl resulted in 13% of cured animals, while similar treatment with ruboxyl-fullerene derivative combination caused 63% curing.

References

.
Impact of antioxidant supplementation on chemotherapeutic toxicity: A systematic review of the evidence from randomized controlled trials
Block K.I., Koch A.C., Mead M.N., Tothy P.K., Newman R.A., Gyllenhaal C.
International Journal of Cancer, 2008
.
Highly selective reactions of C60Cl6 with thiols for the synthesis of functionalized [60]fullerene derivatives.
Khakina E.A., Yurkova A.A., Peregudov A.S., Troyanov S.I., Trush V.V., Vovk A.I., Mumyatov A.V., Martynenko V.M., Balzarini J., Troshin P.A.
Chemical Communications, 2012
.
[60]fullerene is a powerful antioxidant in vivo with no acute or subacute toxicity.
Gharbi N., Pressac M., Hadchouel M., Szwarc H., Wilson S.R., Moussa F.
Nano Letters, 2005
.
Fullerenol-cytotoxic conjugates for cancer chemotherapy.
Chaudhuri P., Paraskar A., Soni S., Mashelkar R.A., Sengupta S.
ACS Nano, 2009
.
Fullerene-based amino acid ester chlorides self-assembled as spherical nano-vesicles for drug delayed release.
Lin M., Chen R., Yu N., Sun L., Liu Y., Cui C., Xie S., Huang R., Zheng L.
Colloids and Surfaces B: Biointerfaces, 2017
.
Synthesis and Εvaluation of Αnticancer Αctivity in Cells of Novel Stoichiometric Pegylated Fullerene-Doxorubicin Conjugates
Magoulas G.E., Bantzi M., Messari D., Voulgari E., Gialeli C., Barbouri D., Giannis A., Karamanos N.K., Papaioannou D., Avgoustakis K.
Pharmaceutical Research, 2014
.
Free-radical Mechanisms in the Cytotoxic Action of Antitumour Antibiotics
Emanuel' N.M., Bogdanov G.N., Orlov V.S.
Russian Chemical Reviews, 1984
.
Voronkov M.V., Volkov V.A., Volkov V.V., Romanova V.S., Plashchina I.G., Sidorsky E.V.
Mendeleev Communications, 2023